LGK-974

For research use only. Not for use in humans.

目录号：S7143 别名： NVP-LGK974, WNT974

LGK-974 Chemical Structure

CAS No. 1243244-14-5

LGK-974 (NVP-LGK974, WNT974)是一种有效的特异性PORCN抑制剂,抑制Wnt信号通路，在TM3细胞中IC50为0.4 nM。Phase 1。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2022.93 现货
RMB 2019.87 现货
RMB 7962.02 现货
有超大折扣
大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck生产的LGK-974发表文献52篇：

产品安全说明书

PORCN抑制剂选择性比较

生物活性

产品描述 LGK-974 (NVP-LGK974, WNT974)是一种有效的特异性PORCN抑制剂,抑制Wnt信号通路，在TM3细胞中IC50为0.4 nM。Phase 1。
特性 LGK-974是口服有效的Porcupine-特异性抑制剂，用于治疗依赖Wnt配体的恶性肿瘤，目前处于I期临床试验阶段。
靶点
Porcn [1]
(TM3 cells)
体外研究

LGK-974在PORCN放射配体结合测定中，可有效取代[3H]GNF -1331，IC50为1 nM，在细胞中达到20µM时也没有很大的细胞毒作用。LGK974抑制所有测试的Wnts，IC50为0.05到2.4 nM，这与PORCN表型的基因缺失一致。[1] LGK974能特异性地抑制三种RNF43突变细胞株HPAF-II, PaTu 8988S, 和 Capan-2的生长。[2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HPAF-II  M3\HbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnrNUDPxE4EoB?= MlzQSG1UVw>? MY\pcohq[mm2czD0bIUh\3Kxd4ToJI9nKHCjbnPy[YF1cWNiY3HuZ4VzKGOnbHygcIlv\XNid3n0bOKhWk6INEPteZRifGmxbtMg NWPBclhkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFczODNpPkKzPFQ4OjB|PD;hQi=>
PaTu 8988S  MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\Wbmd{OSEQvF5CpC=> MXfEUXNQ NXnnc4xYcW6qaXLpeJMhfGinIHfyc5d1cCCxZjDwZY5kemWjdHnjJINidmOncjDj[YxtKGyrbnXzJJdqfGkEoGLOSlQ{dXW2YYTpc47DqA>? MmDIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NEeyNFMoRjJ|OES3NlA{RC:jPh?=
Capan-2 NULwcJhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFqwUYkyKM7:TdMg NX;l[nF[TE2VTx?= M3L1OolvcGmkaYTzJJRp\SCpcn;3eIghd2ZicHHuZ5Jm[XSrYzDjZY5k\XJiY3XscEBtcW6nczD3bZRpyqCUTl[0N:KhdXW2YYTpc44> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2N{KwN{c,OjN6NEeyNFM9N2F-
HPAF-II Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrFNUDPxE4EoB?= NH3heG5FVVOR MXnpcohq[mm2czD0bIUh\3Kxd4ToJI9nKHCjbnPy[YF1cWNiY3HuZ4VzKGOnbHygcIlv\XNid3n0bOKhWk6INERCpI12fGG2aX;u NYTGVJZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFczODNpPkKzPFQ4OjB|PD;hQi=>
PaTu8988S NU\SNZl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYryPYlyOSEQvF5CpC=> M2\D[2ROW09? NYnrfW5PcW6qaXLpeJMhfGinIHfyc5d1cCCxZjDwZY5kemWjdHnjJINidmOncjDj[YxtKGyrbnXzJJdqfGkEoGLOSlQ{yqCvdYTheIlwdg>? M1TVUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OES3NlA{Lz5{M{i0O|IxOzxxYU6=
293T  NVTw[ndPTnWwY4Tpc44hSXO|YYm= M3;3[mlEPTEEoH;mJFAvPCCwTTD0c{BqdmirYnn0d{BYdnRic3nncoFtcW6pIHnuJJRp\SCjZn;y[Y1mdnSrb37l[EBYdnRiY3;jeYx1fXKnIHHzd4F6 MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ5N{i1OEc,OjR{N{e4OVQ9N2F-
293T  MoXvSpVv[3Srb36gRZN{[Xl? NUToS3JzUUN3MDDv[kAyKG6PIITvJINwdXCndHWgc4ZnKFt|SG2tS25HNTF|M{GgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NVXMSHhDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyO|c5PTRpPkK0Nlc4QDV2PD;hQi=>
HT1080 NXf6SVZ7TnWwY4Tpc44h[XO|YYm= M3nkPGlvcGmkaYTpc44hd2ZicH;yZ5VxcW6nIHHjeIl3cXS7IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJIh2dWGwIFjUNVA5OCClZXzsd{Bie3Onc4Pl[EBieyC|dYDwdoV{e2mxbjDv[kBYdnR|QT3t[YRq[XSnZDDzeZBmeiC2b4Cg[oxie2hiYXP0bZZqfHliYomgV3RHKGy3Y3nm[ZJie2ViYYPzZZktKEmFNUCgQUAxNjByMESg{txONg>? NFP3cJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkWyNlk1Pid-Mk[1NlI6PDZ:L3G+
L Wnt3A, HEK293 M3GyUmZ2dmO2aX;uJIF{e2G7 NH\3cnk1QCCqcoO= MnTLTY5pcWKrdHnvckBw\iCZboSgd4lodmGuaX7nJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKG2xdYPlJGwhX262M1GgZ4VtdHNiY3:tZ5VtfHW{ZXSge4l1cCCKRVuyPVMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGP1dIVzNXSxcDDmcIF{cCC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR|UxKD1iMD6wNFA6KM7:TT6= NHi1bY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[0O|MxOyd-Mk[2OFc{ODN:L3G+
L Wnt3A, HEK293 NXXCdlBtTnWwY4Tpc44h[XO|YYm= MWi0PEBpenN? M3HJcWlvcGmkaYTpc44hd2ZicH;yZ5VxcW6nIHnuJI1wfXOnIFygW451O0FiY3XscJMh[29vY4XseJVz\WRid3n0bEBJTUt{OUOgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFO3cHXyMZRweCCobHHzbEBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwJF0hOC5yMEC5JO69VS5? NEXhPGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[5NlUxQSd-Mke2PVI2ODl:L3G+
L Wnt3A, HEK293 MYHGeY5kfGmxbjDhd5NigQ>? MmfIOFghcHK| NGnLS41KdmirYnn0bY9vKG:oIIDvdoN2eGmwZTDpckBud3W|ZTDMJHdvfDODIHPlcIx{KGOxLXP1cJR2emWmIIfpeIghUEWNMkmzJINmdGy|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIGfueEB{cWewYXzpcoch[W[2ZYKgOFghcHK|IHL5JHN2eGW{LYTvdEBndGG|aDDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyIE2gNE4xODB7IN88UU4> M3ezVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEm5OFg{Lz5{OUS5PVQ5OzxxYU6=
HEK293T MVzGeY5kfGmxbjDhd5NigQ>? NXXRdJo1OC5zIIXN M2TkflQ5KGi{cx?= Mk\xTY5pcWKrdHnvckBw\iCyb4LjeZBqdmViKIXub45wf25ib4Lp[4lvMSCrbjDISWszQTOWIHPlcIx{KHS{YX7z[oVkfGWmIIfpeIgheEyrYnnuMXdPXDODIIDsZZNucWRiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKFewdEPBJJNm[3KndHnvckBqdnSxIHPlcIwh[3WudIXy[UBu\WSrdX2gZZQhOC5zIIXNJIFnfGW{IES4JIhzeyCkeTDX[ZN1\XKwIHLsc5QhfGWlaH7pdZVm M4fFR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkS3N|A{Lz5{Nk[0O|MxOzxxYU6=
HEK293T NF\GWotHfW6ldHnvckBie3OjeR?= MXuwMlEhfU1? M3jDZlQ5KGi{cx?= NITPXHVKdmirYnn0bY9vKG:oIIDvdoN2eGmwZTDpckBJTUt{OUPUJINmdGy|IITyZY5{\mWldHXkJJdqfGhicFzpZolvNVeQVEPBJJBt[XOvaXSgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIGfueFNCKHOnY4LleIlwdiCrboTvJINmdGxiY4XseJVz\SCvZXTpeY0h[XRiMD6xJJVOKGGodHXyJFQ5KGi{czDifUBY\XO2ZYLuJIJtd3RibXX0bI9l NF3ocJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[5NlUxQSd-Mke2PVI2ODl:L3G+
BT-12 Mn74dWhVWyCjc4PhfS=> MmPPdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy| MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB1643 M37CWZFJXFNiYYPzZZk> M4H4b5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO= NWDFPYVHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 NWrlWmxjeUiWUzDhd5NigQ>? M4nMRZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= NVn6W2ZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC NVniVmNjeUiWUzDhd5NigQ>? MkD6dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= NY\iUYdZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
HEK293 MX;GeY5kfGmxbjDhd5NigQ>? MVSxNFAhdk1? MkD6OFghcHK| NGrMW4ZKdmirYnn0bY9vKG:oIIDvdoN2eGmwZTDpckBJTUt{OUOgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCyTHnibY4uX06WM1GgdIxie22rZDDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBNWlB4IIDoc5NxcG:{eXzheIlwdiCjdDCxNFAhdk1iYX\0[ZIhPDhiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= MnOxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OUm0PFMoRjJ7NEm5OFg{RC:jPh?=
HEK293T MWTGeY5kfGmxbjDhd5NigQ>? MXexNFAhdk1? MX[0PEBpenN? NVXyPVFVUW6qaXLpeIlwdiCxZjDwc5JkfXCrbnWgbY4hUEWNMkmzWEBk\WyuczD0doFve2[nY4Tl[EB4cXSqIIDMbYJqdi2ZTmSzRUBxdGG|bXnkJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDXcpQ{SSC|ZXPy[ZRqd25iaX70c{Bk\WyuIHP1cJR2emVibXXkbZVuKGG2IEGwNEBvVSCjZoTldkA1QCCqcoOgZpkhX2W|dHXyckBjdG:2IH3leIhw\A>? NYCzNWF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PVk1QDNpPkK5OFk6PDh|PD;hQi=>
PA1 M4rDNGZ2dmO2aX;uJIF{e2G7 NGO3[|czPCCqcoO= NYfNbHpKUW6qaXLpeIlwdiCxZjDwc5JkfXCrbnWtcYVlcWG2ZXSgW451N2KndHGtZ4F1\W6rbjDzbYdv[WyrbnegbY4hcHWvYX6gVGEyKGOnbHzzJIF{e2W|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKEG6aX6yJI1TVkFiZYjwdoV{e2mxbjDh[pRmeiB{NDDodpMh[nlicnXhcE11cW2nIGDDVkBidmGueYPpdy=> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR7OUS4N{c,Ojl2OUm0PFM9N2F-
HEK293 MUTGeY5kfGmxbjDhd5NigQ>? Mkf1NVAxKG6P M3jEVVQ5KGi{cx?= NHHYbIdKdmirYnn0bY9vKG:oIIDvdoN2eGmwZTDpckBJTUt{OUOgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCyTHnibY4uX06WM1GgdIxie22rZDDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBlcXOqZY\lcIVlKDJicHjvd5Bpd3K7bHH0bY9vKGG2IEGwNEBvVSCjZoTldkA1QCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NEnRTo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS5PVQ5Oyd-Mkm0PVk1QDN:L3G+

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
Nrf2 / Wnt3A / HO-1 / NQO-1 / Survivin; 

PubMed: 28627706     


HepG2 cells were treated with LGK-974 at the indicated concentrations and collected after 24 h. Then, we extracted total protein samples for western blot analysis.

NF-κB / IκB / p-IκB; 

PubMed: 28128299     


BEAS-2B human bronchial epithelial cells were pretreated with 0.001–10 nM of LGK974 for 2 hours, followed by 0.1 μg/ml of LPS stimulation for 2 hours. Western blotting was used to assess protein levels and phosphorylation of NF-κB and IκB.

p-LRP6 / Axin / p-GSK3β / p-β-catenin / β-catenin; 

PubMed: 28128299     


BEAS-2B human bronchial epithelial cells were pretreated with 0.001–10 nM of LGK974 for 2 hours, followed by 0.1 μg/ml of LPS stimulation for 2 hours.

28627706 28128299
Immunofluorescence
α1, 6-fucosylation ; 

PubMed: 28798691     


Representative immunofluorescent and Lectin fluorescent images of α1, 6-fucosylation. (Scale bars = 50 μm; Magnification, 400×). 

FUT8; 

PubMed: 28798691     


Representative immunofluorescent and Lectin fluorescent images of FUT8 (Scale bars = 50 μm; Magnification, 400×). 

beta-catenin; 

PubMed: 25639201     


HTM cells treated with 10 μM KY02111 or LGK-974 likewise show a reduction of β-catenin staining intensity.

28798691 25639201
体内研究 LGK-974 (3 mg/kg)作用于小鼠MMTV-WNT1肿瘤模型和人的头部和颈部鳞状细胞癌模型（hn30），抑制 Wnt 信号通路，诱导肿瘤退化且小鼠体重没有明显的下降。[1] LGK-974 (5 mg/kg, p.o., BID) 也能抑制RNF43-突变胰腺肿瘤(HPAF-II 和Capan-2)的生长。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验：[2]
- 合并
  • Cell lines: HPAF-II, PaTu 8988S, 和 Capan-2 细胞
  • Concentrations: ~1 μM
  • Incubation Time: 3 天
  • Method: 细胞以每份密度6,000–12,000个接种在96孔板上，加入 DMSO或1 μM LGK974的培养基培养。3天后，加入新鲜的含有20 μM EdU的培养液，EdU来自Click-iT EdU Alexa Fluor 488 HCS试剂盒，孔板在37°C含有5% CO2的湿润空气温育2小时。用4% (mass/vol) paraformaldehyde固定细胞30分钟，用PBS清洗，渗透，然后用50 μg/mL溶于PBS的Hoechst 染色30分钟。清洗后，根据Click-iT EdU试剂盒的说明检测。在每种条件下每孔进行一式三份。
    (Only for Reference)
动物实验：[1]
- 合并
  • Animal Models: 小鼠MMTV-Wnt1肿瘤模型和人体头颈部鳞状细胞癌模型(HN30)
  • Dosages: ~3 mg/kg 每天
  • Administration: 口服灌胃
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 79 mg/mL warmed (199.27 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
2% DMSO+corn oil
 5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 396.44
化学式

C23H20N6O
CAS号 1243244-14-5
储存条件 粉状
溶于溶剂
别名 NVP-LGK974, WNT974

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量 只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01351103 Recruiting Drug: LGK974|Biological: PDR001 Pancreatic Cancer|BRAF Mutant Colorectal Cancer|Melanoma|Triple Negative Breast Cancer|Head and Neck Squamous Cell Cancer|Cervical Squamous Cell Cancer|Esophageal Squamous Cell Cancer|Lung Squamous Cell Cancer Novartis Pharmaceuticals|Novartis December 1 2011 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    If LGK974 is a lipophilic or hydrophilic substance?

  • 回答：

    LGK974 is a lipophilic compound.

Selleck产品目录册
Tags: 购买LGK-974 | LGK-974供应商 | 采购LGK-974 | LGK-974价格 | LGK-974生产 | 订购LGK-974 | LGK-974代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID